ALK and Grandpharma team up to market the first adrenaline autoinjector in China
July 30, 2021 08:51 ET | ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext®, in China via a partnership with leading supplier of adrenaline, Grandpharma.Jext® is expected to be the...
ALK og Grandpharma indgår partnerskab om markedsføring af den første adrenalinpen i Kina
July 30, 2021 08:51 ET | ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) vil lancere Jext® i Kina via et partnerskab med den førende leverandør af adrenalin, Grandpharma.Jext® forventes at blive den første adrenalinpen på det...
ALK_logo_GlobeNewsWire.png
New, large, ‘real-world evidence’ study by ALK of AIT’s long-term effects on allergy and asthma presented at EAACI Congress
July 10, 2021 05:35 ET | ALK Abello
Leading allergy researchers present data from a new, large, ‘real-world evidence’ study of allergy immunotherapy at EAACI Annual Congress in Krakow, PolandStudy assessed long-term outcomes in allergic...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
May 10, 2021 11:25 ET | ALK Abello
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
May 10, 2021 11:25 ET | ALK Abello
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af...
Three-month interim report (Q1) 2021
May 05, 2021 00:57 ET | ALK Abello
Bemærk venligst, at rapporten foreligger udelukkende på engelsk. ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021...
ALK_logo_GlobeNewsWire.png
Three-month interim report (Q1) 2021
May 05, 2021 00:57 ET | ALK Abello
ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021 represented ALK’s best-ever quarter, with revenue exceeding DKK 1...
ALK_logo_GlobeNewsWire.png
Release date of three-month interim report (Q1) 2021 for ALK and audio cast
April 28, 2021 03:08 ET | ALK Abello
On Wednesday, 5 May 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its three-month interim report (Q1) 2021. ALK will host a meeting for analysts and institutional investors that day at...
Dato for offentliggørelse af delårsrapport for første kvartal 2021 for ALK og webcast
April 28, 2021 03:08 ET | ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første kvartal 2021 onsdag den 5. maj 2021. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer og...
ALK_logo_GlobeNewsWire.png
ALK gains paediatric approval for its ragweed SLIT-tablet in the USA
April 19, 2021 05:40 ET | ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The US Food and Drug Administration has approved extending the current product labelling of RAGWITEK® to include paediatric allergic rhinitis patientsThe...